Cobro Ventures
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Cobro Ventures.
Key people at Cobro Ventures.
Key people at Cobro Ventures.
Cobro Ventures is a US-based private investment firm specializing in biotechnology and technology sectors, particularly software. With a team that has over 25 years of experience as founders, operators, and investors, the firm focuses on supporting early-stage companies through critical phases of innovation by providing capital, expertise, and strategic resources. Their mission centers on "doing well by doing good," aiming to create significant value by backing world-class scientific and technology experts and leveraging intellectual property and business development[2][1][3].
Founded by entrepreneurs behind OPNET Technologies, Inc., Cobro Ventures has a track record of successful exits via IPOs and acquisitions, particularly in biotech and tech startups. Their portfolio includes companies advancing selective HDAC inhibition, targeted protein degradation, synthetic miniprotein therapeutics, AI-guided therapy, and private online community platforms. The firm’s investment philosophy emphasizes impactful innovation and strategic growth in sectors with high scientific and technological potential[2][5].
Cobro Ventures was launched by the founders of OPNET Technologies, leveraging their entrepreneurial and operational experience to transition into venture investing. The firm has evolved to focus primarily on biotech and software startups across the US, building on a 20+ to 25+ year track record of founding and scaling technology businesses. Key partners include Marc A. Cohen (late co-founder and CEO) and Todd Kaloudis (Managing Director and General Partner), who have shaped the firm’s mission and investment approach[2][5][3].
Cobro Ventures rides the wave of rapid innovation in biotechnology and software, sectors driven by advances in molecular biology, AI, and digital transformation. The timing is critical as biotech breakthroughs and software platforms increasingly intersect, creating new therapeutic and technological paradigms. The firm’s influence extends by nurturing startups that push scientific boundaries and digital innovation, thereby shaping the ecosystem of early-stage ventures that fuel long-term industry growth[2][1].
Looking ahead, Cobro Ventures is well-positioned to capitalize on emerging trends such as targeted protein degradation, AI-driven therapies, and digital community platforms. Their continued emphasis on combining deep scientific expertise with operational experience suggests they will remain influential in bridging innovation and commercialization. As biotech and tech sectors evolve, Cobro Ventures’ role as a strategic partner and investor will likely expand, fostering startups that address critical health and technology challenges while generating substantial economic value[2][1].
This outlook ties back to their founding ethos of "doing well by doing good," reflecting a commitment to impactful innovation and sustainable growth in the technology and biotech arenas.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 1, 2022 | NextRNA Therapeutics | $47.0M Series A | — | — |
| Jan 1, 2022 | AI Proteins | $18.0M Seed | — | — |
| Jan 1, 2021 | Mana Therapeutics | $35.0M Series A | — | — |
| Jan 1, 2016 | C4 Therapeutics | $73.0M Series A | — | — |
